US-based TPG will be acquiring a 35% stake in Serum Institute of India (SII) and German firm SCHOTT Pharma's joint venture (JV) SCHOTT Poonawalla. SII had earlier reportedly agreed to sell around 30-40% stake held by it in SCHOTT Poonwalla to TPG. After the acquisition, SII will retain minority stake while SCHOTT Pharma will maintain 50% ownership in the JV.